Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference
29 Febbraio 2024 - 10:30PM
Metagenomi, Inc. (Nasdaq: MGX), a precision genetic
medicines company committed to developing curative
therapeutics for patients using its proprietary,
comprehensive metagenomics-derived gene editing toolbox,
today announced that Brian C. Thomas, CEO & Founder, will
participate in a panel titled, “Emerging Genetic Therapy
Approaches,” during the 44th Annual Cowen Healthcare Conference on
Wednesday, March 6, 2024 from 12:50-1:50 PM ET in Boston.
A live webcast will be available on the "News &
Events," page in the Investors section of the Company's website at
https://ir.metagenomi.co/news-events/events. A replay of the
webcast will be archived on the Metagenomi website for 30 days
following the presentation.
About Metagenomi
Metagenomi is a precision genetic medicines company
committed to developing curative therapeutics for patients
using its proprietary, comprehensive metagenomics-derived
toolbox. Metagenomi is harnessing the power of metagenomics,
the study of genetic material recovered from the natural
environment, to unlock four billion years of microbial
evolution to discover and develop a suite of novel editing
tools capable of correcting any type of genetic mutation found
anywhere in the genome. Its comprehensive genome editing
toolbox includes programmable nucleases, base editors, and
RNA and DNA-mediated integration systems (including prime
editing systems and clustered regularly interspaced short
palindromic repeat-associated transposases. Metagenomi
believes its diverse and modular toolbox positions the
company to access the entire genome and select the optimal tool
to unlock the full potential of genome editing for patients. For
more information, please visit https://metagenomi.co.
Forward‐Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as
amended. Such statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions,
include, but are not limited to, any statements relating to our
growth strategy and product development programs, including the
timing of and our ability to conduct IND-enabling studies, make
regulatory filings such as INDs and other applications and to
obtain regulatory approvals for our product candidates, statements
concerning the potential of therapies and product candidates, and
any other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under, and maintain
financing and strategic agreements and relationships; risks
relating to the results of research and development activities;
risks relating to the timing of starting and completing clinical
trials; uncertainties relating to preclinical and clinical testing;
our dependence on third-party suppliers; our ability to attract,
integrate and retain key personnel; the early stage of products
under development; our need for substantial additional funds;
government regulation; patent and intellectual property matters;
competition; as well as other risks described in “Risk Factors,” in
our Form S-1 Registration Statement filed on January 5, 2024, as
amended, and our other filings we make with the SEC. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in
events, conditions or circumstances on which any such statement is
based, except as required by law, and we claim the protection of
the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.
Investor Contact:Simon Harnest CIO, SVP
Strategysimon@metagenomi.co
Media Contact:Ashlye Hodge Communications
Managerashlye@metagenomi.co
Grafico Azioni Metagenomi (NASDAQ:MGX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Metagenomi (NASDAQ:MGX)
Storico
Da Dic 2023 a Dic 2024